ResMed Management Discusses Q4 2012 Results - Earnings Call Transcript

ResMed (RMD)

Q4 2012 Earnings Call

August 02, 2012 4:30 pm ET


Peter C. Farrell - Founder, Executive Chairman, Chief Executive Officer and President

Brett A. Sandercock - Chief Financial Officer and Principal Accounting Officer

Michael J. Farrell - President of Americas Operations

Donald Darkin - President of SDB Strategic Business Unit

David Pendarvis - Chief Administrative Officer, Global General Counsel and Secretary

Geoff Neilson - President of Respiratory Care Strategic Business Unit

Robert Douglas - Chief Operating Officer


Dan Hurren - UBS Investment Bank, Research Division

Jacob Messina

Michael Matson - Mizuho Securities USA Inc., Research Division

Ben Andrew - William Blair & Company L.L.C., Research Division

Ian Abbott - Goldman Sachs Group Inc., Research Division

Nicholas Cameron - Deutsche Bank AG, Research Division

Anthony Petrone - Jefferies & Company, Inc., Research Division

David Stanton - Nomura Securities Co. Ltd., Research Division

Matthew Prior - BofA Merrill Lynch, Research Division

Saul Hadassin - Crédit Suisse AG, Research Division



Good afternoon, ladies and gentlemen. Welcome to the Fourth Quarter 2012 ResMed, Inc. Earnings Conference Call. My name is Chris, and I will be your conference moderator for today. [Operator Instructions]

The company has asked me to address certain matters: First, ResMed does not authorize the recording of any portion of this conference for any purpose. Second, during the conference call, ResMed may make forward-looking statements, such as projections of future revenue earnings, new product development or new markets for the company's products. These statements are made under the Safe Harbor Provision of the Private Securities Litigation Reform Act of 1995.

If you liked this article you might like

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

ResMed: Cramer's Top Takeaways

Why CarMax and Garmin Could Be Prime Candidates for a Short Squeeze

Why a Massive Short Squeeze Could Send These 4 Stocks Into Orbit

ResMed (RMD) Stock Sharply Lower After Q1 Results Miss Estimates